TIN816
Phase 2Terminated 0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Kidney Injury Following Cardiac Surgery
Conditions
Acute Kidney Injury Following Cardiac Surgery
Trial Timeline
Mar 3, 2023 → Jun 23, 2025
NCT ID
NCT05524051About TIN816
TIN816 is a phase 2 stage product being developed by Novartis for Acute Kidney Injury Following Cardiac Surgery. The current trial status is terminated. This product is registered under clinical trial identifier NCT05524051. Target conditions include Acute Kidney Injury Following Cardiac Surgery.
What happened to similar drugs?
20 of 20 similar drugs in Acute Kidney Injury Following Cardiac Surgery were approved
Approved (20) Terminated (4) Active (0)
✅Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05524051 | Phase 2 | Terminated |
Competing Products
20 competing products in Acute Kidney Injury Following Cardiac Surgery